NASDAQ:RVPH

Reviva Pharmaceuticals Stock Forecast, Price & News

$4.18

+0.10 (+2.45 %)

(As of 04/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.09

Now: $4.18▼

$4.30

50-Day Range

$4.05

MA: $6.29▼

$8.75

52-Week Range

$3.93

Now: $4.18▼

$15.10

Volume8,458 shs

Average Volume30,293 shs

Market Capitalization$38.61 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.04

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and psychotic symptoms, dementia or Alzheimer's disease, parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis; and RP1208 that has completed pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:RVPH

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.revivapharma.com

Phone408 501 8881

Employees5

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.28

Current Ratio0.05

Quick Ratio0.05

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash Flow$0.03 per share

Price / Cash Flow122.91

Book Value$0.60 per share

Price / Book6.97

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$620,000.00

Net MarginsN/A

Return on Equity-13.34%

Return on Assets-1.36%

Miscellaneous

Outstanding Shares9,232,000

Market Cap$38.61 million

Next Earnings Date5/3/2021 (Estimated)

OptionableNot Optionable

Headlines

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Update
April 13, 2021 | americanbankingnews.com

Zacks Investment Research Comments on Reviva Pharmaceuticals Holdings, Inc.'s FY2021 Earnings (NASDAQ:RVPH)
April 8, 2021 | americanbankingnews.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.17 out of 5 stars

Medical Sector

1828th out of 2,025 stocks

Pharmaceutical Preparations Industry

730th out of 772 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Reviva Pharmaceuticals.

0.0 Community Rank

Outperform Votes
Reviva Pharmaceuticals has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Reviva Pharmaceuticals has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Reviva Pharmaceuticals and other stocks. Vote “Outperform” if you believe RVPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RVPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Reviva Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reviva Pharmaceuticals does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 20.60% of the stock of Reviva Pharmaceuticals is held by insiders.
Percentage Held by Institutions
64.11% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Reviva Pharmaceuticals is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Reviva Pharmaceuticals is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Reviva Pharmaceuticals has a P/B Ratio of 6.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$4.18

+0.10 (+2.45 %)

(As of 04/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive RVPH News and Ratings via Email

Sign-up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter.

Reviva Pharmaceuticals (NASDAQ:RVPH) Frequently Asked Questions

What stocks does MarketBeat like better than Reviva Pharmaceuticals?

Wall Street analysts have given Reviva Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Reviva Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Reviva Pharmaceuticals?

Reviva Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,900 shares, an increase of 240.6% from the March 15th total of 3,200 shares. Based on an average daily volume of 31,600 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the shares of the company are sold short.
View Reviva Pharmaceuticals' Short Interest.

When is Reviva Pharmaceuticals' next earnings date?

Reviva Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Reviva Pharmaceuticals.

Who are Reviva Pharmaceuticals' key executives?

Reviva Pharmaceuticals' management team includes the following people:

Dr. Laxminarayan Bhat, Founder, CEO, Pres & Director (Age 55, Pay $247.95k)
Mr. Narayan Prabhu, Chief Financial Officer (Age 49)
Dr. Marc Cantillon, Chief Medical Officer (Age 62)

Who are some of Reviva Pharmaceuticals' key competitors?

Some companies that are related to Reviva Pharmaceuticals include SCYNEXIS (SCYX), Catalyst Biosciences (CBIO), Galecto (GLTO), Exicure (XCUR), Eledon Pharmaceuticals (ELDN), Actinium Pharmaceuticals (ATNM), Aquestive Therapeutics (AQST), AcelRx Pharmaceuticals (ACRX), Concert Pharmaceuticals (CNCE), Palatin Technologies (PTN), Anixa Biosciences (ANIX), Eyenovia (EYEN), Synlogic (SYBX), IMARA (IMRA) and Odonate Therapeutics (ODT).
View all of RVPH's competitors.

What is Reviva Pharmaceuticals' stock symbol?

Reviva Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVPH."

How do I buy shares of Reviva Pharmaceuticals?

Shares of RVPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reviva Pharmaceuticals' stock price today?

One share of RVPH stock can currently be purchased for approximately $4.18.

How much money does Reviva Pharmaceuticals make?

Reviva Pharmaceuticals has a market capitalization of $38.61 million.

How many employees does Reviva Pharmaceuticals have?

Reviva Pharmaceuticals employs 5 workers across the globe.

What is Reviva Pharmaceuticals' official website?

The official website for Reviva Pharmaceuticals is www.revivapharma.com.

How can I contact Reviva Pharmaceuticals?

The company can be reached via phone at 408 501 8881.

This page was last updated on 4/23/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here